Computed from published fixed rules, not a model's judgement — though one input, the count of high-severity risks, comes from the AI analysis below.
Not investment advice and not a price target: it scores the quarter's fundamentals, not the stock. Full methodology →
AI Takeaway
Pfizer reported Q1 2026 revenue of $14.45B (+5.4% YoY), but net income declined 9.4% to $2.69B as cost of revenue surged 24.7%, compressing margins despite improved operating cash flow of $2.62B.
Revenue
$14.45B
+5.37% YoY
EPS (Diluted)
$0.47
-9.62% YoY
Source: SEC XBRL
Pfizer (PFE) reported Q1 FY2026 revenue of $14.45B, up 5.4% year over year. Operating cash flow was $2.62B, up 12.0% year over year. PFE's fiscal Q1 FY2026 corresponds to calendar Q1 2026.
Last 4 quarters: 4 beats
| Quarter | Actual EPS (USD) | Consensus (USD) | Result |
|---|---|---|---|
| Jun 2026 | 0.77 | 0.69 | Beat +11.4% |
| Mar 2026This filing | 0.75 | 0.72 | Beat +3.5% |
| Dec 2025 | 0.66 | 0.58 | Beat +14.3% |
| Sep 2025 | 0.87 | 0.64 | Beat +36.0% |
Adjusted (non-GAAP) EPS of $0.75 versus the $0.72 analyst consensus — a +3.5% beat for Mar 2026. Analyst consensus is quoted on the adjusted (non-GAAP) basis the street uses. GAAP diluted EPS for this quarter was $0.47.
Compiled by AI from this SEC filing
Total revenue increased 5.4% YoY to $14.45B in Q1 2026 from $13.72B in Q1 2025, suggesting continued demand recovery across Pfizer's product portfolio beyond the COVID-era peak.
Source: 10-Q Income Statement, Q1 2026
Cost of revenue jumped 24.7% YoY to $3.55B from $2.85B, significantly outpacing revenue growth of 5.4% and indicating rising manufacturing costs, product mix shifts, or inventory-related charges that compressed gross margins.
Source: 10-Q Income Statement, Q1 2026
SG&A expenses declined 2.3% YoY to $2.96B from $3.03B, reflecting ongoing cost-reduction initiatives that partially mitigated the impact of higher production costs on operating income.
Source: 10-Q Income Statement, Q1 2026
Operating cash flow rose 12.0% YoY to $2.62B from $2.34B, outpacing net income of $2.69B, supported by D&A of $1.61B, suggesting solid underlying cash generation even as reported earnings declined.
Source: 10-Q Cash Flow Statement, Q1 2026
Long-term debt rose 5.1% YoY to $60.57B, while financing cash outflows narrowed significantly to -$2.86B from -$5.23B, indicating reduced shareholder returns or debt repayments compared to the prior year period.
Source: 10-Q Balance Sheet & Cash Flow Statement, Q1 2026
Compiled by AI from this SEC filing · 2 high, 2 medium, 1 low
Cost of revenue grew at 24.7% YoY, nearly five times the revenue growth rate of 5.4%, driving net margin down to 18.6% from approximately 21.6% in the prior year period. If this cost trend persists, it could materially erode Pfizer's profitability even as top-line growth continues.
Source: 10-Q Income Statement, Q1 2026
Long-term debt stands at $60.57B, representing a debt-to-equity ratio of 1.30x, which is a significant leverage level for a pharmaceutical company. Rising interest rates or refinancing needs could increase interest expense and constrain financial flexibility.
Source: 10-Q Balance Sheet, Q1 2026
Net income fell 9.4% YoY to $2.69B and diluted EPS declined to $0.47 from $0.52, despite revenue growth, signaling that cost pressures are translating directly into lower shareholder returns. Sustained EPS compression could weigh on investor sentiment.
Source: 10-Q Income Statement, Q1 2026
Investing cash flow dropped 76.0% YoY to $785M from $3.27B, which may reflect reduced proceeds from asset sales or lower investment activity. This could limit Pfizer's ability to replenish its pipeline through acquisitions or capital expenditures.
Source: 10-Q Cash Flow Statement, Q1 2026
The current ratio stands at 1.25x with current assets of $42.82B against current liabilities of $34.35B, and cash & equivalents of only $1.70B. While technically adequate, the thin cash position relative to the company's scale leaves limited room for unexpected near-term obligations.
Source: 10-Q Balance Sheet, Q1 2026
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue $B | 14.45 $B | 13.72 $B | +5.37% |
Cost of Revenue $B | 3.55 $B | 2.85 $B | +24.71% |
Net Income $B | 2.69 $B | 2.97 $B | -9.44% |
EPS (Basic) $ | 0.47 $ | 0.52 $ | -9.62% |
EPS (Diluted) $ | 0.47 $ | 0.52 $ | -9.62% |
SG&A Expense $B | 2.96 $B | 3.03 $B | -2.31% |
Answers draw on this SEC filing and the data on this page
Pfizer's Q2 FY2026 revenue grew 3% to $15.0 billion, but a $3 billion impairment and legal charge drove a net loss of $248 million, even as operating cash flow surged 97% year-over-year.
Pfizer's FY2025 10-K shows a modest revenue decline of 1.6% to $62.6B alongside improved cost discipline, resulting in net income of $7.8B and solid operating cash flow of $11.7B, though rising long-term debt warrants attention.
Other companies in Pharmaceuticals